Podcasts about Cancer research

Today, I'm flying solo for a deep—well, more like a just-scratching-the-surface—dive into one of the body's most fascinating hormones: melatonin. After getting so many of your questions about how melatonin really works, whether it's just about sleep, and how it might support healthy aging, I decided to tackle all those hot topics head-on in this episode.   Download my FREE guide to my top 5 peptides for longevity:  https://www.natniddam.com/top5   What we discuss: Why melatonin is complex; plans for future episodes ... 00:00:42 Melatonin as darkness hormone; comparison with vitamin D ... 00:01:51 Top science-backed facts about melatonin ... 00:03:25 Light exposure's impact and blue light mitigation tips ... 00:05:09 Bioidentical melatonin in plants and animals; supplement notes ... 00:06:41 Production in pineal gland and gut; unique roles ... 00:07:24 Melatonin decline with age and rationale for supplementation ... 00:09:02 Calcified pineal gland and bioregulator benefits ... 00:10:03 Melatonin's antioxidant, skin, mitochondrial, and anti-cancer effects ... 00:10:37 High-dose melatonin in research and cancer ... 00:12:21 Melatonin from food—phytomelatonin vs. synthetic ... 00:18:37 Supplements: dependency, dosing, and genetic factors ... 00:21:57 Practical tips for dosing and timing ... 00:23:22 Potential drug interactions and safety ... 00:27:38 Wide-ranging health impacts and future research ... 00:28:26 Product recommendations and tracking results ... 00:29:55   Our Amazing Sponsor: OraltidePro  - A unique mouthwash that: Promotes growth of shrinking gums, Speeds healing of mouth & tongue, Prevents oral infections (such as gingivitis), Helps with enamel remineralization, Reduces bacteria growth and etching and Fills slots in damaged enamel. check out OraltidePro at profound-health.com and use code NAT15 for 15% off your first order.   More from Nat:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Join Dr. Kristi Funk, M.D., FACS, as she explains how obesity increases cancer risk by focusing on inflammation, estrogen production, and leptin levels. Discover the benefits of exercise in reducing cancer risk, improving overall health, and enhancing chemotherapy outcomes. Learn about key lifestyle changes to lower breast cancer risk and explore the resources and support available at the Pink Lotus Breast Center. #CancerPrevention #HealthyLiving #BreastCancerAwareness

Hey Heal Squad! Today, Maria sits down with physician and researcher Dr. William Makis to explore the deeper patterns emerging in our health! They discuss topics like why so many people are experiencing unexplained fatigue, chronic inflammation, and even earlier cancer diagnoses (what?!). Dr. Makis shares why our immune systems are more overwhelmed than ever, and how environmental stressors are taxing the body's natural ability to heal. He breaks down what's changed in the past few years, what warning signs to look for, and how to support your body so it stays resilient and strong. You'll learn how to recognize the early red flags of immune dysfunction, what lifestyle choices could be feeding inflammation, and what it really takes to create an internal environment where your body can protect and restore itself. This is your sign to take care of your wellness from the inside out! Tune in!!  HEALERS & HEAL-LINERS:  Chronic inflammation is a warning sign. Many cancers and autoimmune conditions begin with low-level inflammation that goes unchecked, tuning into early symptoms like fatigue, brain fog, or skin changes can help you take action before bigger issues arise. Your immune system is your greatest defense. When supported properly (through sleep, light, nutrition, and detox), your immune system can identify and destroy abnormal cells before they become disease. The “new normal” isn't normal. More people are experiencing mystery symptoms, early cancer, and immune dysfunction, Dr. Makis will help you understand why it's happening and how to reverse course. -- HEAL SQUAD SOCIALS IG: https://www.instagram.com/healsquad/ TikTok: https://www.tiktok.com/@healsquadxmaria HEAL SQUAD RESOURCES: Heal Squad Website:https://www.healsquad.com/ Heal Squad x Patreon: https://www.patreon.com/HealSquad/membership Maria Menounos Website: https://www.mariamenounos.com My Curated Macy's Page: Shop My Macy's Storefront Prenuvo: Prenuvo.com/MARIA for $300 off Delete Me: https://bit.ly/43rkHwi   code: SQUAD EMR-Tek Red Light: https://emr-tek.com/discount/Maria30 for 30% off Airbnb: https://www.airbnb.com/  Join In-Person Heal Retreat Waitlist! https://mariamenounos.myflodesk.com/heal-retreat-waitlist GUEST RESOURCES: Instagram: https://www.instagram.com/wmakismd/?hl=en  Website: https://www.twc.health/  For anyone wanting more information on how Ivermectin, fenbendazole, and mebendazole works, or need dosing protocols, connect with Dr. Makis makisw79@yahoo.com Or visit his Substack makismd.substack.com ABOUT MARIA MENOUNOS: Emmy Award-winning journalist, TV personality, actress, 2x NYT best-selling author, former pro-wrestler and brain tumor survivor, Maria Menounos' passion is to see others heal and to get better in all areas of life. ABOUT HEAL SQUAD x MARIA MENOUNOS: A daily digital talk-show that brings you the world's leading healers, experts, and celebrities to share groundbreaking secrets and tips to getting better in all areas of life. DISCLAIMER: This Podcast and all related content (published or distributed by or on behalf of Maria Menounos or http://Mariamenounos.com and http://healsquad.com) is for informational purposes only and may include information that is general in nature and that is not specific to you. Any information or opinions provided by guest experts or hosts featured within website or on Company's Podcast are their own; not those of Maria Menounos or the Company. Accordingly, Maria Menounos and the Company cannot be responsible for any results or consequences or actions you may take based on such information or opinions. This podcast is presented for exploratory purposes only. Published content is not intended to be used for preventing, diagnosing, or treating a specific illness. If you have, or suspect you may have, a health-care emergency, please contact a qualified health care professional for treatment.

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jacob Moshokoa, in for Pippa Hudson, speaks to Dr. Sahar Abdul-Rasool, a senior lecturer at UWC’s Department of Medical Biosciences UWC, about developing techniques to spot cancer markers even when there’s just one rogue cell among ten million. Lunch with Pippa Hudson is CapeTalk’s mid-afternoon show. This 2-hour respite from hard news encourages the audience to take the time to explore, taste, read and reflect. The show - presented by former journalist, baker and water sports enthusiast Pippa Hudson - is unashamedly lifestyle driven. Popular features include a daily profile interview #OnTheCouch at 1:10pm. Consumer issues are in the spotlight every Wednesday while the team also unpacks all things related to health, wealth & the environment. Thank you for listening to a podcast from Lunch with Pippa Hudson Listen live on Primedia+ weekdays between 13:00 and 15:00 (SA Time) to Lunch with Pippa Hudson broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/MdSlWEs or find all the catch-up podcasts here https://buff.ly/fDJWe69 Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Tokenized stocks have long been a crypto dream, but are they real yet? Gabriel Otte, founder of Dinari, joins to break down the current landscape. We cover what tokenized stocks actually are, why regulatory hurdles make them complex, how Dinari secured the first broker-dealer license for tokenized public shares, and what this means for on-chain finance. We also explore the limitations of current tokenized stock offerings, Robinhood's moves, and whether true DeFi composability is possible for equities. ------

Hi! I've made some big changes, and had some big sales, so let's catch up Galaxians!I'm riding in the Great Cycle Challenge to raise money for Kids' Cancer Research! I've pledged 300 miles in September! I'll do the miles, but I need you to give, please donate if you can! Thanks! https://greatcyclechallenge.com/riders/RyanShoemakerMy New Cycling Channel: https://www.youtube.com/@cycling-with-ryanCycling With Ryan Instagram https://www.instagram.com/cycling_with_ryan0:00 Intro1:18 Thank you to my viewers and listeners2:55 What's changing on this show9:51 New Cycling Channel Announcement14:31 What SoldMy Website: https://linktr.ee/galaxycdsrocksMy Ebay Store: https://ebay.us/HD2CAsMy Curated eBay Supply Store: https://www.ebay.com/inf/galaxycdsrocksMy Etsy Shop: https://www.etsy.com/shop/GalaxyCDSI've created a series of Reselling Logs, and Personal Journals, which you can see on Amazon! https://amzn.to/3pJPkqDGalaxy CDS Rocks Swag Store: https://galaxy-cds-rocks.creator-spring.comDonations to the channel accepted at: https://www.paypal.me/galaxycdsMy Channel Ethics Statement Regarding Sponsorships: https://docs.google.com/document/d/1UmRx77pe_F9kmiG4VlkDuy8Kmq32hJvY1n2COf5ImZY/edit?usp=sharingStuff I use: (These are sponsored affiliate links, and by using them you will support the podcast when I receive a small commission payment from the site for referring you, at no additional cost to you. So click away Galaxians!)I use Streamyard for my Podcast Interviews and Upcoming Live Shows. I highly recommend it! https://bit.ly/49spdKcHave a need to crosslist? Try ListPerfectly! I recently signed up and am in the process of moving over 6000 listings from eBay to Mercari, watch for future updates! Use this referral link, be sure to input referral code 634 and save 30% off your first month, please and thank you! https://listperfectly.com/?ref=634Sign Up with Mercari! It's easy to buy and sell on Mercari. Get up to $20 when you get started. Use code RPSYYJ when you sign up with my link: https://merc.li/bWdhq8kVb #mercariPodcast/YouTube GearOBSBOT Tiny 2 Lite Camera: https://amzn.to/40QVOYxElgato Stream Deck: https://amzn.to/468lvHEHollyland Lark M2 Microphone: https://amzn.to/44IELcfReselling ToolsValue Mailers on eBay for All Of Your Package Needs: https://ebay.us/Sqif0Ebeeprt Bluetooth 4x6 Thermal Label Printer: https://amzn.to/3Oiu61aScotty Peeler Label Remover: https://amzn.to/3rnpp8nTape King Tape Gun: https://amzn.to/2WjFPBzPlease smash that thumbs up, share, and subscribe!Sound effects obtained from https://www.zapsplat.com

For this "Summer Friday" we've put together some of our favorite conversations this year:Natalie Wynn, creator of the YouTube channel Contrapoints, discusses her work including her latest video titled "CONSPIRACY" in which she delves into the history of conspiracies in American politics, the allure of conspiratorial thinking, and how this way of thought negatively impacts democracy.James Sanders, architect, author, filmmaker, and co-writer with Ric Burns of the PBS series: New York: A Documentary Film and its companion volume, New York: An Illustrated History (Knopf, 2021) and the author of Celluloid Skyline: New York and the Movies (Knopf, 2001), talks about the New York seen in films since the beginning of movie-making, as part of our centennial series.Each year the news division hosts the WNYC Health Convening with support from the Alfred P. Sloan Foundation as an opportunity for health care experts and practitioners to inform WNYC's health reporting. This year, as part of our centennial series "100 Years of 100 Things," Paul Goldberg, editor and publisher of The Cancer Letter, co-editor of The Cancer History Project, and author of The Dissident (Farrar, Straus, and Giroux, 2023), discusses the century of cancer treatment advancements and how the U.S. government played a major part in funding the science for treatment, early detection and prevention.The WNYC Health Convening with support from the Alfred P. Sloan Foundation continues with a look at the current state of cancer research in the United States.Sudip Parikh, Ph.D., chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals;Otis Brawley, professor of oncology at The Kimmel Cancer Center at Johns Hopkins, a Bloomberg Distinguished Professor at Johns Hopkin and co-editor of The Cancer History Project; andJulie Rovner, chief Washington correspondent at KFF Health News and host of the What the Health? podcast; discuss what the impacts of the Trump administration's funding cuts to the National Health Institute have meant to clinical trials—and what a future without government funding to find a cure might look like should the science continue to be underfunded. These interviews were lightly edited for time and clarity and the original web versions are available here:Contrapoints' Natalie Wynn Deep Dives into the Philosophy of Conspiracies (May 29, 2025)100 Years of 100 Things: New York Films (May 19, 2025)100 Years of 100 Things: Cancer Research (Jun 3, 2025)A Roundtable on the Current State of U.S. Cancer Research (Jun 3, 2025)

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this enlightening episode of Keeping Abreast, Dr. Jenn sits down with world-renowned surgical oncologist Dr. Francisco Contreras to explore how mindset, metabolic therapy, and integrative medicine can change the cancer care conversation.Guided by the influence of his father, a pioneer in holistic oncology, Dr. Contreras shares his path to becoming a surgeon and his mission to treat not just the disease, but the whole person. From patient empowerment to the limitations of conventional care, this episode offers a deep dive into the emotional, spiritual, and metabolic components of healing.You'll hear how innovative therapies at Oasis of Hope combine conventional medicine with holistic practices—and why patient education is the cornerstone of long-term success.This conversation is filled with hope, science, and practical insights to help you take charge of your healing journey.In This Episode, You Will Learn:How Dr. Contreras's father inspired his holistic cancer care approachWhy mindset and empowerment are critical in healingThe science behind metabolic therapy and low-glycemic nutritionWhat immunotherapy is—and how it's changing cancer outcomesHow alternative and conventional treatments can work togetherWhy movement, habit-building, and diet play vital roles in recoveryThe truth about high-dose vitamin C, off-label meds, and natural remediesHow innovative treatments like dendritic cell vaccines and CAR T cells workWhy patients deserve education, options, and hope

Send us a textDaniel Schmitt is President & Chief Executive Officer of Actuate Therapeutics, Inc. ( https://actuatetherapeutics.com/ ), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β).Mr. Schmitt brings over 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of multiple pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies, totaling nearly $1 billion in upfront and potential milestone payments.Mr. Schmitt received his M.B.A and a B.S. in Chemistry from West Virginia University, and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina School of Medicine. He has served as an Entrepreneur-in-Residence at Northwestern University, and as an external expert consultant for the University of Chicago and the University of Illinois-Chicago. Mr. Schmitt is also a founding member of Chicago Innovation Mentors.#ActuateTherapeutics #GlycogenSynthaseKinase3Beta #GSK3β #Oncology #Cancer #Elraglusib #PancreaticDuctalAdenocarcinoma #PDAC #EwingSarcoma #Melanoma #ProgressionFreeSurvival #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sandi DuBowski discusses the one-year anniversary of his film Sabbath Queen, which he spent 21 years making. He reflects on the journey of the 21st-century radical rabbi and how it has shaped their life. He discusses the inspiration behind his film, Tomboychik, the concept of which was developed after conversations with his grandmother. The film is a living video memorial to her spirit; it won several awards, including the Golden Gate award at the San Francisco Film Festival and the Whitney Museum program, and launched Sandi into the film world. Documentary Films and Festivals  Sandi talks about his work as an associate director of the New York Lesbian/Gay Experimental Film Video festival, MIX. He initially worked on a feature film called Fresh Kill and later worked for Planned Parenthood as a researcher and producing videos. After working for Planned Parenthood, he started filming the major feature documentary, Trembling Before G-d, about Hasidic and Orthodox Jews who are lesbian or gay. The film had a World Premiere at Sundance, and won two prizes at the Berlin Film Festival. It screened in cinemas and festivals worldwide, and Sandi went on the road for three years, doing outreach and engagement. Sandi concludes by expressing gratitude for the support and funding he received from the Steven Spielberg Righteous Persons Foundation. He also mentions that his film Sabbath Queen has been a significant moment in his life, as he reconnects with classmates from Harvard, high school, elementary school, film, queer, Jewish, and activist circles. The film has been a testament to the power of storytelling and the transformative power of time. Breaking from Traditional Religious Conventions Sandi fell into the world of filmmaking by accident. He worked with great people, including cinematographers and editors, to create a team of creatives. The film "Trembling Before G-d" was a significant leap forward in technical craft and embraced the lives of people who were not in the public realm. The first Orthodox gay Rabbi came out in the film, and the first person from a Hasidic world to come out as lesbian was featured. The film also convinced Orthodox rabbis to speak publicly on the issue, which was a tipping point in the culture. The filmmaker met with Amichai, who was already post-denominational and pushing the boundaries of Orthodoxy. Sandi talks about the film's concept and how it inspired a Muslim man to make a movie on Islam and homosexuality. Filming the Documentary Sabbath Queen Sandi shares the journey of filming Sabbath Queen, which involved following Rabbi Amichai over 21 years. The film took six years to edit due to multiple storylines, nearly 3000 hours of footage, and time spent exploring Amichai's complex identity and his numerous worlds within his rabbinic family. The film was a complicated project, but Sandi and Amichai have remained close friends. The film is Biblical in many ways, as it is a coming of age and a paradigm shift from a thousands-year-old faith to the present. The film aims to address the challenges faced by religion, as well as the rise of authoritarianism and fascism. Sandi believes that creating a film that looks at time and how values can be manifested in our lives, communities, families, houses of worship, and nations is crucial for upholding values and morals. A Documentary Filmmaker's Journey Sandi shares his experiences and lessons learned from his journey as a documentary filmmaker. He explains that his life has been unexpected and doesn't fit neatly into boxes. He also shares his experience with Good Pitch, a platform that focuses on social issue documentaries and collaborations with filmmakers. He has built a strong community around films and the film movement, which has been translated into his work with Sabbath Queen. He believes that film communities intersect with many other communities, creating an outpouring of connection and networks. One of the ways Sabbath Queen is promoting community is through live rituals and gatherings. In Berlin, he hosted a Sabbath Queen Friday night feast with Rabbi Amichai, which encouraged togetherness, peacemaking, and reflection. In San Francisco, they hosted a SoulSpa and in Chicago a Saturday night Let the Light In. Sandi also talks about expanded cinema and the importance of gathering, him co-founding a progressive group called The Creative Resistance with media makers and a Queens Food Caravan. Sandi discusses the importance of having creative collaborators who provide feedback and help in the process of creating a character-driven film. He mentions that it is crucial to have test screenings and feedback screenings to help filmmakers work on their work over time. Influential Harvard Professors and Courses Sandi mentions a History and Literature course on the Vietnam War. The course focused on the interdisciplinary nature of storytelling and history, which helped Sandi understand how we process our lives, stories, wounds, and traumas.  Timestamps: 03:28: Early Film Projects and Personal Exploration  12:34: Transition to Long-Term Documentary Filmmaking 22:01: Challenges and Rewards of Long-term Filmmaking  22:23: Personal Life and Community Building  22:41: Advice for Long-term Documentary Filmmakers  41:35: Impact of Sabbath Queen and Future Plans Featured Non-profit: The featured non-profit of this episode of The 92 Report is recommended by Mark Jacobstein, class of ‘92, who reports: “Hi. I'm Mark Jacobstein, class of 1992. The feature nonprofit of this episode of The 92 Report is The Friends of Cancer Research. The Friends of Cancer Research powers advances in science and policy that speed life saving treatments to patients. I'm proud to have worked with them during my time at Garden Health and found that they were by far the most important and effective 501, C3, in the world of cancer research. You can learn more about their work at Friends of Research, friends of cancer research.org, and now here's Will Bachman with this week's episode.” To learn more about their work, visit: FriendsofCancerResearch.org.  

Join Dr. Kristi Funk as she breaks down breast cancer risk factors into "Boulders" and "Pebbles." Learn why diet, nutrition, alcohol, exercise, and obesity are major factors, and how you can reduce your risk. This insightful talk empowers you to take control of your health. #BreastCancerAwareness #HealthyLiving #CancerPrevention

Text Dr. Lenz any feedback or questions This detailed podcast episode delves into the findings of a study on Chronic Fatigue Syndrome (CFS) using functional MRI and immune system analysis. The speaker explains the technology behind functional MRI and what it revealed about brain activity, specifically in the parietal temporal junction, which showed hypoactivity in CFS patients. The discussion extends to immune abnormalities, highlighting immune cell exhaustion, and hypothesizing links to persistent infections. The episode emphasizes the need for interdisciplinary, evidence-based approaches to treating these 'invisible' illnesses and calls for more integrated, patient-centric research. Other discussed topics include the limitations of current medical specialization and the need for generalist knowledge, the role of gut microbiome, and potential lessons from oncology on immune checkpoints.00:00 Introduction to Functional MRI01:48 Understanding Functional MRI Findings04:08 Immune System Insights04:54 Cancer Research and Immune Exhaustion09:01 Genetic Susceptibility and Long COVID10:33 Holistic Approach to Medicine13:34 Challenges in Treating CFS and Fibromyalgia15:38 Future Directions in Research22:40 Gut Microbiome and Immune Response25:41 Neurodivergence and Immune System29:25 Conclusion and Final Thoughts International Conference on ADHD in November 2025 where Dr. Lenz will be one of the speakers. Support the showWhen I started this podcast—and the book that came before it—I had my patients in mind. Office visits are short, but understanding complex, often misunderstood conditions like fibromyalgia takes time. That's why I created this space: to offer education, validation, and hope. If you've been told fibromyalgia “isn't real” or that it's “all in your head,” know this—I see you. I believe you. You're not alone. This podcast aims to affirm your experience and explain the science behind it. Whether you live with fibromyalgia, care for someone who does, or are a healthcare professional looking to better support patients, you'll find trusted, evidence-based insights here, drawn from my 28+ years as an MD. Please remember to talk with your doctor about your symptoms and care. This content doesn't replace personal medical advice.* ...

I wasn't sure what to expect going into this conversation with Chris Harrison—but I walked away with a deeper respect for a man who's been through a public firestorm and came out of it more grounded, more thoughtful, and more self-aware. For nearly two decades, Chris was the host of The Bachelor—a pop culture staple. But we didn't spend our time rehashing old seasons. Instead, we talked about the real stuff: identity, regret, resilience, and what it means to be publicly misunderstood. Chris opened up about the moment everything changed, how it impacted him personally and professionally, and how he handled the silence that followed. He talked about therapy, fatherhood, the power of taking ownership, and why losing his job may have been one of the best things that ever happened to him. And through it all, there was no bitterness—just clarity. Chris showed up with humility and honesty, and I think you'll hear that right away. This is a conversation about redemption, reinvention, and what happens when the spotlight turns off and you're left with who you really are. Chapters: 00:00 – Intro: First impressions and why this conversation matters 02:00 – Life after The Bachelor and learning to let go 06:00 – The 2021 controversy: what happened, and how he handled it privately 12:30 – The weight of silence: losing his voice in the public square 18:00 – Owning mistakes, navigating cancel culture, and why words matter 24:00 – Therapy, humility, and starting the inner work 30:00 – Rebuilding relationships and letting go of the need to be “right” 36:00 – Fatherhood and how his kids saw it all unfold 42:00 – What he lost—and what he found in the quiet 48:00 – Why he never rushed a comeback 53:00 – Launching The Most Dramatic Podcast Ever and finding his own voice 01:00:00 – The highs and lows of hosting The Bachelor 01:08:00 – Fame, pressure, and identity outside the spotlight 01:15:00 – Manhood, grace, and how his definition of success has changed 01:25:00 – Final reflections: peace, purpose, and what's next Check out LifeRX.MD  Code: STEELE About Sage:  Sage Steele is a longtime national TV broadcaster and current host of The Sage Steele Show on YouTube and all podcast platforms. From 2007 to 2023, she was a mainstay at ESPN, anchoring SportsCenter and leading coverage of major events like the Super Bowl, The Masters, NBA Finals, and the World Series. She also hosted NBA Countdown on ESPN and ABC from 2013–2017. Outside of sports, Sage has hosted national broadcasts including the Miss America Pageant, Scripps National Spelling Bee, the Rose Parade, and ABC's Volcano Live with Nik Wallenda. She's appeared on The View, Jimmy Kimmel Live, and has been featured in Rolling Stone, Variety, and The Wall Street Journal. A graduate of Indiana University, Sage began her journalism career in local news before rising to regional and national prominence. She now serves on the boards of the Boys & Girls Clubs of America and The V Foundation for Cancer Research. She's a proud mom of three and currently resides in Florida. Subscribe to the Channel for more Podcasts like this! Listen to the Show on all Podcast Apps "The Sage Steele Show" https://podcasts.apple.com/us/podcast/the-sage-steele-show/id1737682826 Follow Sage: https://www.sagesteele.com https://x.com/sagesteele https://www.instagram.com/sagesteele https://www.tiktok.com/@officialsagesteele https://rumble.com/c/SageSteeleProductions Learn more about your ad choices. Visit megaphone.fm/adchoices

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

The US makes up 80% of the entire world's biomedical research. Donald Trump's slashing of NIH funding is setting the country on track for a "lost generation of scientists." The amount of money being taken from cancer research alone, is 18x smaller than the proposed tax breaks for the top .001% in Trump's budget bill. Ali Velshi explains. 

This is episode three of Swimming with Shadows: A Radiolab Week of Sharks.Today, we take a trip across the world, from the south coast of Australia to … Wisconsin. Here, scientists are scouring shark blood to find one of nature's hidden keys, a molecular superhero that might unlock our ability to cure cancer: shark antibodies. They're small. They're flexible. And they can fit into nooks and crannies on tumors that our antibodies can't.We journey back 500 million years to the moment sharks got these special powers and head to the underground labs transforming these monsters into healers. Can these animals we fear so much actually save us? Special thanks to Mike Criscitiello, David Schatz, Mary Rose Madden, Ryan Ogilvie, Margot Wohl, Sofi LaLonde, and Isabelle Bérubé.EPISODE CREDITS: Reported by - Becca BresslerProduced by - Becca Bressler and Matt KieltyOriginal music from - Matt Kielty and Jeremy BloomSound design contributed by - Matt Kielty, Jeremy Bloom, and Becca Bresslerwith mixing help from - Jeremy BloomFact-checking by - Diane Kellyand Edited by  - Pat WaltersSignup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Join me in the latest Dog Gone Positive Way episode as I interview Cindy, who started Scout and Zoe's Unique Treats, Food, and Chews. In this episode, we delve into International business trade. The Middle East and Asia are just a few international areas that will be introduced to Scout and Zoe's Unique Treats, Chews, and Food. Cindy also started a 501(c)(3) SCOUTING FOR A CURE, to raise funds for cancer research in dogs and cats. You can also donate to memorialize your pet and your funds will go towards Cancer Research. A disease I know many of us have experienced, saying goodbye to our pets when they pass away from cancer and go to the Rainbow Bridge.Cindy is tackling the invasive species of fish known as Carp. Cindy's love of dogs and all pets fuels this unique company's passion. From Carp Bubblers, kangaroo jerky, trout heads, duck heads, tendons, and everything in between, you will find amazing treats and food, and chews that will keep your pets happy, healthy, busy, and nourished.10% off CODE: Bubblers GO TO scoutandzoes.com You can find Cindy on social media @scoutandzoes#InternationalTrade #cancer #dog #puppy #cat #kitten #podcast #treats #rainbowbridge #dogmom #cancerresearch

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textSend me feedback hereDr. Bobby begins with a walk through his local deli, which sparked a deeper investigation into what actually goes into processed meats. He outlines how processed meats are defined by the USDA as those altered through salting, curing, or smoking for preservation, dating back to Paleolithic food practices. The real concern, he explains, lies in compounds like nitrates (NO3) and nitrites (NO2), which can convert into nitrosamines, a group of chemicals potentially linked to colorectal cancer.Citing the American Institute for Cancer Research and the International Agency for Research on Cancer, Dr. Bobby notes that processed meats have been labeled carcinogenic, with consumption linked to an increased cancer risk. However, he contrasts this with a weak recommendation from the Nutritional Recommendations Consortium, which found low-certainty evidence that processed meat increases cancer risk, suggesting most people could continue their usual consumption patterns.He scrutinizes observational studies like the UK Biobank study and a meta-analysis of 15 studies involving 2.5 million participants, both hinting at a modest increased risk but fraught with methodological flaws such as poor adjustment for confounders like diet, exercise, and lifestyle habits.The conversation deepens with the Shanghai study that found nitrate-related cancer risk only in individuals with low vitamin C intake, pointing to the potentially protective effects of antioxidants. Supporting this, Dr. Bobby highlights that 70% of dietary nitrates come from vegetables like spinach and beets, which are associated with lower cancer risk, adding nuance to the nitrate debate.And it gets more paradoxical—beetroot juice rich in nitrates has been shown in 75 randomized controlled trials to lower blood pressure by up to 7 points systolic, rivaling medication.To put things into perspective, Dr. Bobby crunches the numbers: if processed meats raise colorectal cancer risk by 13%, your lifetime risk might increase from 4% to 4.4%—a marginal difference. In real terms, out of 1,000 people who completely avoid processed meats, only four might avoid colorectal cancer.Other additives like sodium erythorbate and sodium ascorbate appear non-problematic at normal levels, and while sodium may raise blood pressure in salt-sensitive individuals, it's not linked to cancer risk—explored further in Episode 27.Dr. Bobby closes with a pragmatic and humor-tinged "bacon hack": since vitamin C may counteract the formation of harmful nitrosamines, consider enjoying your bacon with a glass of orange juice—a personal theory grounded in biochemical plausibility but not tested.Takeaways: If you enjoy processed meats, the absolute cancer risk appears minimal based on current evidence. Leafy vegetables, despite their high nitrate content, are protective—likely due to vitamin C and other antioxidants. To balance pleasure and prudence, pair your bacon with a side of vitamin C, and above all, remember: wellne

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: FDA approves new drug for treatment of rare genetic diseaseIn a significant development for the rare disease community, the FDA has approved a new drug for the treatment of a rare genetic disease. The drug, which is the first of its kind, has shown promising results in clinical trials and is expected to provide much-needed relief for patients suffering from this condition.##News 2: Biotech company announces breakthrough in cancer researchA leading biotech company has announced a major breakthrough in cancer research. The company's new treatment has shown significant efficacy in treating a variety of cancers, offering hope to patients who previously had limited treatment options. This development marks a significant step forward in the fight against cancer.##News 3: Pharma company reports positive results in COVID-19 vaccine trialsA pharmaceutical company has reported positive results in clinical trials for its COVID-19 vaccine candidate. The vaccine has shown high efficacy rates in preventing infection and reducing the severity of symptoms in vaccinated individuals. This news comes as a welcome development in the ongoing battle against the global pandemic.##News 4: Biotech startup secures funding for innovative gene therapyA promising biotech startup has secured funding for its innovative gene therapy approach. The therapy, which targets a range of genetic disorders, has shown promising results in preclinical studies and is now moving towards clinical trials. This funding will help accelerate the development of the therapy and bring it one step closer to market availability.##News 5: Pharma giant announces collaboration with leading research institutionA major pharmaceutical company has announced a collaboration with a leading research institution to advance drug discovery efforts. The partnership aims to leverage the expertise of both organizations to accelerate the development of new treatments for a variety of diseases. This collaboration represents a significant step forward in the quest for innovative therapies.##News 6: Biotech conference showcases latest advancements in gene editing technologyA recent biotech conference showcased the latest advancements in gene editing technology. Researchers presented cutting-edge techniques that have the potential to revolutionize the field of genetic engineering. These advancements hold promise for developing new treatments for a wide range of diseases and disorders.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the world of pharmaceuticals and biotechnology. Thank you for listening!

It's a controversial topic - but with communal discipline still common in many cultures, does it truly take a village to raise a child? And if so, how do you establish the norms in your own community. Helen puts it to three parenting experts. Meanwhile, as a major oncology conference in the USA hears how cancer patients are now delaying or refusing treatment in favour of miracle diets, essential oils and advice from TikTok influencers with no medical qualifications, Helen factchecks some medical claims with breast cancer surgeon turned patient, Dr Liz O'Riordan. We get the facts on healthcare before travel, and vaccine catch-ups, with Dr Howard Podolsky, and Tom Poulson from Haus&Haus is also on hand to talk property buying mistakes, and how to avoid them. See omnystudio.com/listener for privacy information.

Three of our favorite segments from the week, in case you missed them.Katie Barnes, award-winning LGBTQ sports journalist, on trans women and girls in sport (First) | A recap of the first NYC mayoral debate (Starts at 47:30) | A 100-year history of Cancer research in the United States (Starts at 1:25:10)If you don't subscribe to the Brian Lehrer Show on iTunes, you can do that here.

Expanding access to clinical trials in community oncology settings is essential to improving diversity, equity, and inclusion in cancer research. In this episode, CANCER BUZZ speaks with clinical research coordinator, Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP, whose cancer center recently participated in a foundational oncology clinical trials course, developed by ACCC and the Association of Clinical Research Professionals (ACRP) to help cancer programs expand availability of trials to traditionally underserved communities. Oladipupo shares how this training prepared their center for the challenges of a growing research program, the progress they've made, and the pivotal role of clinical research coordinators in expanding research programs and improving patient access to clinical trials.   Oluwakemi “Kemi” Oladipupo, MSHS, MPH, BSN, RN, CCRP Clinical Research Coordinator Touro-Cancer Center New Orleans, LA   “We know that diversity is a big point, not only as per new FDA guidance, but [to] ensure that every participant is given an equal opportunity to hear about the study. [Our] approach is not to target a certain group of individuals. Really the approach is to target any individual that looks potentially eligible.” - Oluwakemi “Kemi” Oladipupo   Resources:  Community Oncology Can Close the Gap in Cancer Research Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator The Role of the Clinical Trials Navigator — [MINI PODCAST] EP 129 Human-Centered Design: A Possible Solution to Rural Clinical Trial Enrollment

You can go to my sponsor https://aura.com/sagesteele to try 14 days for free. That's enough time for Aura to start scrubbing your personal info off these data broker sites, without you lifting a finger. Kirk Cameron joined me for a conversation that hit deeper than I expected. If you're thinking of the teen idol from Growing Pains, sure, that's part of his story. But today, Kirk's a husband, a dad of six (four adopted), a new grandfather, and someone who's been unafraid to speak out about his faith and values. This wasn't just a conversation—it was a reminder that purpose, connection, and peace of mind are choices. Kirk doesn't preach; he shares. And that's why this episode matters. Chapters: 03:39 – Backyard chickens, socks, and moving to Tennessee 06:01 – Duck hunting memories and Phil's legacy 11:41 – Baptism story and spiritual transformation 15:01 – Peace of mind, daily faith practice, and handling loss 21:31 – How Kirk found Christianity at 17 during Growing Pains 26:01 – Kirk's faith unintentionally brings his whole family to church 32:21 – Faith, courage, and what we choose to worship 36:01 – Falling in love with Chelsea and becoming “Chief” 39:01 – Marriage longevity and the power of forgiveness 43:01 – Why marriage is delayed in today's culture 47:01 – Raising kids with faith and purpose 51:01 – Parenting adult kids and grandparenting joy 56:01 – The adoption story: four kids before two biological 01:00:01 – Multiracial family dynamics and identity About Kirk: Kirk Cameron is a lifelong actor, husband, father of six, and committed Christian. Best known as “Mike Seaver” on the hit '80s sitcom Growing Pains, Kirk went on to star in Fireproof, Left Behind, and Lifemark, and produced the documentaries Monumental and The Homeschool Awakening. With his wife Chelsea, he co-founded Camp Firefly, a free summer camp for families of terminally ill children. He also hosts Takeaways with Kirk Cameron and One on One with Kirk Cameron on TBN, and continues to speak out through his American Campfire Revival tour and podcast. Kirk recently authored the children's book As You Grow, encouraging Biblical values and character for the next generation. About Sage: Sage Steele is a longtime national TV broadcaster and current host of The Sage Steele Show on YouTube and all podcast platforms. From 2007 to 2023, she was a mainstay at ESPN, anchoring SportsCenter and leading coverage of major events like the Super Bowl, The Masters, NBA Finals, and the World Series. She also hosted NBA Countdown on ESPN and ABC from 2013–2017. Outside of sports, Sage has hosted national broadcasts including the Miss America Pageant, Scripps National Spelling Bee, the Rose Parade, and ABC's Volcano Live with Nik Wallenda. She's appeared on The View, Jimmy Kimmel Live, and has been featured in Rolling Stone, Variety, and The Wall Street Journal.A graduate of Indiana University, Sage began her journalism career in local news before rising to regional and national prominence. She now serves on the boards of the Boys & Girls Clubs of America and The V Foundation for Cancer Research.She's a proud mom of three and currently resides in Florida. Subscribe to the Channel for more Podcasts like this! Listen to the Show on all Podcast Apps "The Sage Steele Show" https://podcasts.apple.com/us/podcast/the-sage-steele-show/id1737682826 Follow Sage: https://www.sagesteele.com https://x.com/sagesteele https://www.instagram.com/sagesteele https://www.tiktok.com/@officialsagesteele https://rumble.com/c/SageSteeleProductions Follow Kirk: @kirkcameronofficial @bravebooks.us braveplus.com (http://braveplus.com/) Learn more about your ad choices. Visit megaphone.fm/adchoices

- Understanding the Future of Cancer Research & Clinical Trials - Increased Focus on Earlier Detection & Treatment of Cancer - Health Care Disparities Research - Enhanced Knowledge of the Molecular Portrait of Cancer - Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer - Microsatellite Instability (MSI): Mutations in DNA Mismatch Repair Genes – Implications for Treatment - Immunotherapy - CAR T-Cell Therapy - Immune Checkpoint Inhibitors & Blockade - Monoclonal Antibodies - Cancer Treatment Vaccines - Immune System Modulators - Targeted Immunotherapies - Radiopharmaceutical Therapy (RPT) - Antibody-Drug Conjugates (ADCs) - Robotic Surgery - Additional Focus on Lifestyle, Exercise, Nutrition & Hydration - Increasing Role of Telehealth/Telemedicine Appointments - Questions for Our Panel of Experts

- Understanding the Future of Cancer Research & Clinical Trials - Increased Focus on Earlier Detection & Treatment of Cancer - Health Care Disparities Research - Enhanced Knowledge of the Molecular Portrait of Cancer - Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer - Microsatellite Instability (MSI): Mutations in DNA Mismatch Repair Genes – Implications for Treatment - Immunotherapy - CAR T-Cell Therapy - Immune Checkpoint Inhibitors & Blockade - Monoclonal Antibodies - Cancer Treatment Vaccines - Immune System Modulators - Targeted Immunotherapies - Radiopharmaceutical Therapy (RPT) - Antibody-Drug Conjugates (ADCs) - Robotic Surgery - Additional Focus on Lifestyle, Exercise, Nutrition & Hydration - Increasing Role of Telehealth/Telemedicine Appointments - Questions for Our Panel of Experts

- Understanding the Future of Cancer Research & Clinical Trials - Increased Focus on Earlier Detection & Treatment of Cancer - Health Care Disparities Research - Enhanced Knowledge of the Molecular Portrait of Cancer - Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer - Microsatellite Instability (MSI): Mutations in DNA Mismatch Repair Genes – Implications for Treatment - Immunotherapy - CAR T-Cell Therapy - Immune Checkpoint Inhibitors & Blockade - Monoclonal Antibodies - Cancer Treatment Vaccines - Immune System Modulators - Targeted Immunotherapies - Radiopharmaceutical Therapy (RPT) - Antibody-Drug Conjugates (ADCs) - Robotic Surgery - Additional Focus on Lifestyle, Exercise, Nutrition & Hydration - Increasing Role of Telehealth/Telemedicine Appointments - Questions for Our Panel of Experts

- Understanding the Future of Cancer Research & Clinical Trials - Increased Focus on Earlier Detection & Treatment of Cancer - Health Care Disparities Research - Enhanced Knowledge of the Molecular Portrait of Cancer - Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer - Microsatellite Instability (MSI): Mutations in DNA Mismatch Repair Genes – Implications for Treatment - Immunotherapy - CAR T-Cell Therapy - Immune Checkpoint Inhibitors & Blockade - Monoclonal Antibodies - Cancer Treatment Vaccines - Immune System Modulators - Targeted Immunotherapies - Radiopharmaceutical Therapy (RPT) - Antibody-Drug Conjugates (ADCs) - Robotic Surgery - Additional Focus on Lifestyle, Exercise, Nutrition & Hydration - Increasing Role of Telehealth/Telemedicine Appointments - Questions for Our Panel of Experts

The New York Times reports that "President Trump proposed chopping funding at the National Cancer Institute by more than $2.7 billion, nearly a 40 percent decrease." It's part of a significant cut to the National Institutes of Health. Our guests work in cancer research and treatment. They discuss the possible impact of this news, as well as the state of cancer care. In studio: Jonathan Friedberg, M.D., MMSc, director of Wilmot Cancer Institute  Charles Kamen, Ph.D., MPH, associate director for community outreach and engagement at  Wilmot Cancer Institute and associate professor in the Departments of Surgery and Psychiatry at the University of Rochester Medical Center Emily Hayes, MPA, program manager for community outreach and engagement at Wilmot Cancer Institute

Each year the news division hosts the WNYC Health Convening with support from the Alfred P. Sloan Foundation as an opportunity for healthcare experts and practitioners to inform WNYC's health reporting. This year, as part of our centennial series "100 Years of 100 Things," Paul Goldberg, editor and publisher of The Cancer Letter and co-editor of The Cancer History Project, discusses the century of cancer treatment advancements and how the U.S. government played a major part in funding the science for treatment, early detection and prevention.

This year's WNYC Health Convening with support from the Alfred P. Sloan Foundation continues with a look at the current state of cancer research in the United States. Sudip Parikh, Ph.D., chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals, and Otis Brawley, professor of oncology at The Kimmel Cancer Center at Johns Hopkins, a Bloomberg Distinguished Professor at Johns Hopkin and co-editor of The Cancer History Project, and Julie Rovner, chief Washington correspondent at KFF Health News and host of the What the Health? podcast, discuss what the impacts of the Trump administration's funding cuts to the National Health Institute have meant to clinical trials, and what a future without government funding to find a cure might look like should the science continue to be underfunded.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Artificial intelligence is reshaping our world – but what does that mean for healthcare, scientific discovery, and human potential? In Genesis: Artificial Intelligence, Hope, and the Human Spirit, co-authors Craig Mundie, Henry Kissinger, and Eric Schmidt explore the profound implications of AI on society. In this collaborative event between Town Hall Seattle and the Institute for Systems Biology (ISB), Craig Mundie joins Dr. Jim Heath, President of ISB, for a thought-provoking conversation about the future of AI. They will discuss insights from the book, the opportunities and challenges AI presents, and what it means for the way we live, work, and care for our health. Co-author, Genesis: Artificial Intelligence, Hope, and the Human Spirit, Craig Mundie is a leading technology executive and former Chief Research and Strategy Officer at Microsoft. Over his decades-long career, he has played a pivotal role in advancing artificial intelligence, computing, and national security initiatives. Alongside Henry Kissinger and Eric Schmidt, he co-authored Genesis, a deep exploration of AI's impact on society and the future of humanity. Mundie has served as an advisor to the U.S. government on technology policy and was a member of the President's Council of Advisors on Science and Technology. President and Professor, Institute for Systems Biology (ISB) Dr. Jim Heath is a pioneering scientist in systems biology, cancer research, and precision medicine. Since 2018, he has led ISB, driving interdisciplinary research in cancer and immune system dynamics while advancing innovative approaches to complex diseases. An internationally recognized scientist, Heath has received numerous honors, including the Irving Weinstein Award from the American Association for Cancer Research and the Sackler Prize in the Physical Sciences. Before ISB, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech and a Professor of Molecular and Medical Pharmacology at UCLA. Presented by Town Hall Seattle and Institute for Systems Biology. Buy the Book Genesis: Artificial Intelligence, Hope, and the Human Spirit Elliott Bay Book Company

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Losing her job, her security, and even her teeth weren't enough to silence Sage Steele, host of The Sage Steele Show and former ESPN sportscaster. On this special episode of The Narrative, Sage candidly shares why she left ESPN as well as her testimony of courage, conviction, and the sustaining power of prayer at our Cincinnati Celebration Gala. Before Sage takes the stage, CCV President Aaron Baer and Communications Director Mike Andrews sit down to discuss the school choice wins in the One, Big, Beautiful Bill. They also discuss a movement by statewide pastors and ministry leaders to oppose Senate Bill 197, Ohio's gambling expansion bill, and how this bill would impact the most vulnerable. More about Sage Steele Sage Steele is one of the country's most popular and respected broadcasters of her generation. She currently hosts The Sage Steele Show, a weekly podcast, where she sits down with entertainers, athletes, business people, and politicians to have deep dive personal one-on-one discussions that enlighten, entertain, and engage. Prior to launching her show, she was a leading fixture at ESPN from 2007-2023, hosting the network’s flagship show, SportsCenter. Through the years, Sage has been a featured guest host on ABC's The View, was a guest on Jimmy Kimmel Live, and has been profiled by numerous publications, including Rolling Stone, Variety, The Wall Street Journal, Vibe, and Huffington Post. Sage is proud to be a new member of the board of directors for The Boys & Girls Club of America. She is also in her third year as a board member for The V Foundation for Cancer Research, an advisory board member for the Multiple Myeloma Research Foundation (MMRF) and volunteers with The Alzheimer’s Association. Most importantly, Sage is the proud mother of three children, and she resides in Florida.

It's a big day at WCCO, not just Chad's birthday but its the Cure Blood Cancer Radio Auction in partnership with NMDP! Chad is joined by Todd Peterson who is the Executive Director with NMDP. Chad and Todd talk about what brought him to working with NMDP and the interactions they have with people when they reach out to the organization after being touched by blood cancer.. They take bids on the Twins Executive Balcony package where 20 ticket winners join Chad Hartman, Dave Harrigan for the Thursday, June 26th 12:10p game vs Seattle Mariners. The experience includes fully catered food & beverage from one of the coolest private viewing spots at Target Field! In the second half of the hour Chad and Dave take bids on the TPC/3M Package which includes golf/tee times for 4 at the exclusive TPC club in Blaine...PLUS, 4 tickets to the 3rd round at the 3M Open, on Saturday July 26th - which includes a concert that evening with country music recording & touring artist Lee Brice.

Join Dr. Kristi Funk as she debunks the myth about protein intake and reveals top plant-based sources. Learn why you don't need to worry about protein deficiency and discover the power of soy, lentils, beans, and more. Transform your diet with these delicious and nutritious options! #PlantBasedProtein #HealthyEating #BreastCancerPrevention

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On the next Charlotte Talks, we look at the treatment, screening and testing options for prostate cancer patients. We also look at promising new treatment research recently released by Duke University and hear from a prostate cancer survivor.

Philippa Charles, Director of the DFN Charitable Foundation, leads a conversation on the Foundation's strategic philanthropic approach and its distinctive commitment to long-term, systems-level impact. With a background in leading one of the UK's major family foundations and now at the helm of DFN, she offers a compelling look at how deeply personal motivations can shape focused and effective grantmaking. The DFN Foundation operates across four thematic pillars: disability education, disability employment, myeloma cancer research, and conservation. These areas are not only strategic but are also rooted in the lived experiences and values of the Foundation's founding family. This grounding translates into a uniquely empathetic and effective model of philanthropy—one that combines substantial funding with strategic oversight and deep engagement with delivery partners. The episode explores how DFN supports systemic change in disability inclusion. Philippa discusses the success of Undershaw, a school for students with special educational needs that recently received an “Outstanding” rating from Ofsted, and the DFN Project SEARCH initiative, which has helped more than 3,000 young people with disabilities secure meaningful employment across over 200 corporate and public sector partners. These stories illustrate DFN's commitment not just to education and training but to shifting the broader landscape of opportunity for disabled individuals. A similarly strategic approach underpins the Foundation's investment in myeloma research. Through the Jacquelin Forbes Nixon Fellowship, DFN has supported a clinical trial at the Institute of Cancer Research that is producing transformative outcomes. Over 75% of participants remain in remission—a significant improvement over standard care—and the research now points toward wider clinical application and deeper exploration into treatment efficacy and patient outcomes. DFN's work extends beyond the UK, particularly in conservation. In Kenya, the Foundation supports the Pangolin Project, an initiative preserving 5,000 hectares of biodiverse forest and protecting the world's most trafficked and critically endangered mammal. The project embodies the Foundation's ability to balance localized impact with global relevance, and its philosophy of acting where there is both clear need and the opportunity for catalytic intervention. Throughout the discussion, Philippa reflects on the leadership demands of running a multifaceted family foundation. She shares how she is structuring her first year in the role by focusing on governance, partnerships, operational strategy, and long-term vision. Her insights offer a valuable roadmap for those leading or advising mission-driven organizations, especially those navigating the complexities of family philanthropy. The conversation concludes with a discussion of collaboration across the sector and the importance of peer networks among foundations. Philippa also speaks passionately about the transformative power of volunteering, not only as a form of civic engagement but as a professional and personal development tool. For those interested in strategic philanthropy, disability inclusion, evidence-based research funding, and conservation efforts with measurable impact, this episode provides a thoughtful and informative exploration of how one foundation is driving change across sectors—anchored in personal values, executed with professional discipline, and amplified through strategic partnerships. Thank you for downloading this episode of the Do One Better Podcast. Visit our Knowledge Hub at Lidji.org for information on 300 case studies and interviews with remarkable leaders in philanthropy, sustainability and social entrepreneurship.  

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The National Institutes of Health is the largest public funder of biomedical research in the world, but under the Trump administration, NIH is freezing funding to several universities, including Northwestern. One of the projects being delayed is cutting-edge research on ovarian and pancreatic cancer. Reset learns more about the effect of this freeze on patients and early career scientists with Josh Leonard, professor of chemical and biological engineering at Northwestern University. For a full archive of Reset interviews, head over to wbez.org/reset.

- Green Tea and Cognitive Benefits (0:10) - Critique of Pharmaceuticals and Big Pharma (2:39) - Green Tea and Brain Health (4:31) - Speed Cubing and Cognitive Training (10:47) - Green Tea and Cancer Prevention (15:59) - Green Tea and Heavy Metal Detoxification (24:45) - L-Theanine and Anxiety Relief (30:04) - Catechins and Polyphenols in Green Tea (36:21) - Green Tea Extracts and Supplements (39:14) - Green Tea and Cancer Therapy (50:57) - Colloidal Silver and Its Benefits (1:11:38) - Silver Nanoparticles and Cancer Research (1:23:02) - Historical and Metaphysical Significance of Metals (1:26:08) - Economic and Political Implications of Metals (1:27:53) - Challenges and Opportunities in Health and Science (1:30:08) - Personal Reflections and Future Plans (1:37:17) - Final Thoughts and Gratitude (1:41:15) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

Today's Headlines: The State Department is getting a major overhaul, with Secretary Marco Rubio slashing overseas posts and U.S.-based staff by 15%, calling the agency bloated and politically biased. Meanwhile, the Pentagon will soon require women in combat roles to meet the same physical standards as men under a new "sex-neutral" fitness test. Over at HHS, Secretary RFK Jr. is compiling a national autism registry using private medical records, aiming to prove the condition's cause by September. At Harvard, groundbreaking cancer research has stalled because ICE is detaining the scientist who wrote the analysis software—she's now fighting deportation to Russia. Student loan borrowers in default could see their wages garnished starting in May, ending a pandemic-era pause. And Tesla reported a 71% drop in profits, partly due to Elon Musk's political baggage—but its carbon credit sales are booming. Resources/Articles mentioned in this episode: NY Times: Marco Rubio Shares Plans for Overhaul of State Department  NY Times: Female Soldiers Will Have to Pass ‘Sex-Neutral' Physical Test, U.S. Army Says The New Republic: RFK Jr. Set to Launch Disease Registry Tracking Autistic People  NBC News: New images could change cancer diagnostics, but ICE detained the Harvard scientist who analyzes them AP News: Student loans in default to be referred to debt collection, Education Department says WSJ: Tesla Profit Sinks, Hurt by Backlash Over Elon Musk's Political Role Morning Announcements is produced by Sami Sage alongside Bridget Schwartz and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices